Zenlabs Ethica

Why is Zenlabs Ethica Ltd falling/rising?

As of 06-Jul, Zenlabs Ethica Ltd's stock price is at 35.60, down 0.56%, and has underperformed its sector today. The stock shows weakening momentum with a 3.78% decline over the past month, contrasting with a 5.44% increase in the benchmark Sensex, alongside decreased investor participation.

As of 06-Jul, Zenlabs Ethica Ltd's stock price is currently at 35.60, reflecting a decrease of 0.2 or 0.56%. The stock has underperformed its sector by 0.62% today and has experienced a trend reversal, falling after three consecutive days of gains. Additionally, the stock's delivery volume has decreased significantly, with a drop of 29.52% compared to the 5-day average, indicating a decline in investor participation. <BR><BR>While the stock is trading above its moving averages for various periods, the recent performance suggests a weakening momentum. Over the past month, the stock has declined by 3.78%, contrasting with a 5.44% increase in the benchmark Sensex. This underperformance over the short term, combined with falling investor interest, contributes to the current decline in the stock price.

Which are the latest news on Zenlabs Ethica?

Should I buy, sell or hold Zenlabs Ethica Ltd?

What does Zenlabs Ethica do?

Zenlabs Ethica Ltd, a micro-cap company in the diversified commercial services industry, reported net sales of 11 Cr for March 2026 and has a market cap of INR 23 Cr. The company, formerly known as Neelkanth Technologies, has a P/E ratio of 158.00 and no dividend yield.

Overview:<BR>Zenlabs Ethica Ltd operates in the diversified commercial services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was initially incorporated as Neelkanth Technologies Limited in 1993 and changed its name to Zenlabs Ethica Limited in the financial year 2016-17. The most recent quarterly results reported net sales for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 11 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: N/A<BR>- Market-cap: INR 23 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 158.00<BR>- Industry P/E: 20<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 1.29<BR>- Return on Equity: 1.65%<BR>- Price to Book: 2.73<BR><BR>Contact Details:<BR>Address: Plot No 194-195 3rd Flr Pha-II, Industrial Area Ram Darbar Chandigarh Chandigarh ( U T ) : 160002<BR>Tel: 91-172-4651105/3920738<BR>Email: queries@zenlabsethica.com<BR>Website: http://www.zenlabsindia.com; www.zenlabsethica.com

How big is Zenlabs Ethica?

As of 10th June, Zenlabs Ethica Ltd has a market capitalization of 23.00 Cr and reported Net Sales of 46.92 Cr with a Net Profit loss of 1.94 Cr over the latest 4 quarters. Shareholder's Funds were 10.43 Cr and Total Assets were 40.38 Cr as of March 2025.

As of 10th June, Zenlabs Ethica Ltd has a market capitalization of 23.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Zenlabs Ethica reported Net Sales of 46.92 Cr. However, the company experienced a Net Profit loss of 1.94 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 10.43 Cr and Total Assets were reported at 40.38 Cr.

Who are in the management team of Zenlabs Ethica?

The management team of Zenlabs Ethica includes Sanjeev Kumar (Managing Director & CEO), Him Jyoti (Director), Ashok Kumar Gupta (Independent Director), Sanjay Dhir (Whole Time Director & CFO), Anurag Malhotra (Independent Director), Kuldeep Singh (Director), Hitesh Popatlal Oswal (Executive Director), and Akshay Saxena (Company Secretary & Compliance Officer).

The management team of Zenlabs Ethica includes the following individuals:<BR><BR>1. **Sanjeev Kumar** - Managing Director & CEO<BR>2. **Him Jyoti** - Director<BR>3. **Ashok Kumar Gupta** - Independent Director<BR>4. **Sanjay Dhir** - Whole Time Director & CFO<BR>5. **Anurag Malhotra** - Independent Director<BR>6. **Kuldeep Singh** - Director<BR>7. **Hitesh Popatlal Oswal** - Executive Director<BR>8. **Akshay Saxena** - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or responsibilities, feel free to ask!

Who are the peers of the Zenlabs Ethica?

Zenlabs Ethica's peers include Esaar (India), Kaarya Facilit., ERP Soft Systems, Gemstone Invest., Shukra Bullions, Sawaca Enterpri., Vrundavan Planta, and Jayatma Enterp. In terms of management risk, Zenlabs Ethica is rated Average, with its 1-year return at 5.46%, significantly lower than Kaarya Facilit.'s 289.97% and higher than ERP Soft Systems' -53.55%.

Peers: The peers of Zenlabs Ethica are Esaar (India), Kaarya Facilit., ERP Soft Systems, Gemstone Invest., Shukra Bullions, Sawaca Enterpri., Vrundavan Planta, and Jayatma Enterp.<BR><BR>Quality Snapshot: Excellent management risk is observed at Esaar (India) and Gemstone Invest., while Average management risk is found at Zenlabs Ethica, and Below Average management risk is present at Kaarya Facilit., ERP Soft Systems, Shukra Bullions, Sawaca Enterpri., Vrundavan Planta, and the rest. Growth is rated as Good at Esaar (India) and Vrundavan Planta, while Zenlabs Ethica, Kaarya Facilit., ERP Soft Systems, Gemstone Invest., Shukra Bullions, and Sawaca Enterpri. are rated Below Average, and Jayatma Enterp. does not qualify. In terms of Capital Structure, Excellent ratings are given to Esaar (India) and Gemstone Invest., while Zenlabs Ethica has an Excellent rating, and Below Average ratings are found at Kaarya Facilit., ERP Soft Systems, Shukra Bullions, Sawaca Enterpri., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kaarya Facilit. at 289.97%, while the peer with the lowest is ERP Soft Systems at -53.55%. Zenlabs Ethica's 1-year return is 5.46%, which is significantly lower than Kaarya Facilit. and higher than ERP Soft Systems. Additionally, peers with negative six-month returns include ERP Soft Systems, Gemstone Invest., and Sawaca Enterpri.

Are Zenlabs Ethica Ltd latest results good or bad?

Zenlabs Ethica Ltd's latest results are poor, showing a net profit of ₹0.00 crores and an 18.55% decline in revenue year-on-year, alongside a shrinking operating margin and low return on equity. Investors should be cautious due to the company's deteriorating financial health and high valuation relative to industry standards.

Zenlabs Ethica Ltd's latest results indicate a troubling performance. In Q4 FY26, the company reported a net profit of ₹0.00 crores, reflecting a complete collapse in profitability with a 100% decline year-on-year. Revenue also fell significantly, down 18.55% year-on-year to ₹10.58 crores, marking the weakest quarterly performance in the available dataset. Additionally, the operating margin shrank to 2.65%, down from 5.08% in the same quarter last year.<BR><BR>The overall financial health of the company appears to be deteriorating, with a negative trajectory in key metrics. The return on equity (ROE) stands at a mere 6.60%, which is below industry standards, indicating inefficiency in generating returns for shareholders. Furthermore, the company's valuation is concerning, trading at a high P/E ratio of 102.32x, which is significantly above the industry average of 23x.<BR><BR>While the stock has shown extreme volatility, surging 89.80% year-to-date, this price movement seems disconnected from the underlying business fundamentals, raising questions about sustainability. The lack of institutional interest and the presence of significant operational challenges suggest that the recent stock performance may be speculative rather than indicative of a turnaround in the company's fortunes.<BR><BR>In summary, the latest results for Zenlabs Ethica Ltd are decidedly bad, characterized by declining revenues, zero profitability, and weak operational metrics. Investors should approach with caution given the significant risks highlighted by these financial results.

When is the next results date for Zenlabs Ethica Ltd?

The next results date for Zenlabs Ethica Ltd is 29 May 2026.

The next results date for Zenlabs Ethica Ltd is scheduled for 29 May 2026.

How has been the historical performance of Zenlabs Ethica?

Zenlabs Ethica has experienced a decline in net sales and profits from Mar'22 to Mar'25, with net sales dropping from 69.09 Cr to 51.42 Cr and profit after tax decreasing from 1.26 Cr to 0.27 Cr. However, cash flow from operations improved significantly, rising to 3.00 Cr in Mar'25 from a negative 9.00 Cr in Mar'24.

Answer:<BR>The historical performance of Zenlabs Ethica shows a declining trend in net sales and profit over the past few years, with net sales decreasing from 69.09 Cr in Mar'22 to 51.42 Cr in Mar'25. The total operating income followed a similar pattern, dropping from 69.09 Cr in Mar'22 to 51.42 Cr in Mar'25. Operating profit (PBDIT) also saw fluctuations, peaking at 3.04 Cr in Mar'23 before falling to 2.61 Cr in Mar'25. Profit before tax decreased from 1.89 Cr in Mar'19 to 0.43 Cr in Mar'25, while profit after tax declined from 1.26 Cr in Mar'19 to 0.27 Cr in Mar'25. The earnings per share (EPS) reflected this downward trend, decreasing from 1.94 in Mar'19 to 0.41 in Mar'25. <BR><BR>In terms of assets and liabilities, total assets increased from 33.65 Cr in Mar'20 to 40.38 Cr in Mar'25, while total liabilities also rose from 31.75 Cr in Mar'21 to 40.38 Cr in Mar'25. The company maintained a consistent share capital of 6.51 Cr over the years, and reserves grew from 0.90 Cr in Mar'20 to 3.92 Cr in Mar'25. Cash flow from operating activities improved to 3.00 Cr in Mar'25 from a negative 9.00 Cr in Mar'24, indicating a recovery in operational cash generation. Overall, while Zenlabs Ethica has experienced challenges in revenue and profit, there are signs of improvement in cash flow from operations.<BR><BR>Breakdown:<BR>Zenlabs Ethica's financial performance has shown a notable decline in net sales, which fell from 69.09 Cr in Mar'22 to 51.42 Cr in Mar'25, reflecting a consistent downward trend over the years. Total operating income mirrored this decline, decreasing from 69.09 Cr to 51.42 Cr in the same period. Operating profit (PBDIT) peaked at 3.04 Cr in Mar'23 but subsequently dropped to 2.61 Cr in Mar'25. Profit before tax also decreased significantly from 1.89 Cr in Mar'19 to 0.43 Cr in Mar'25, while profit after tax fell from 1.26 Cr to 0.27 Cr over the same timeframe. Earnings per share (EPS) declined from 1.94 in Mar'19 to 0.41 in Mar'25, indicating reduced profitability for shareholders. On the balance sheet, total assets increased from 33.65 Cr in Mar'20 to 40.38 Cr in Mar'25, alongside a rise in total liabilities from 31.75 Cr to 40.38 Cr. The company maintained a stable share capital of 6.51 Cr and saw its reserves grow from 0.90 Cr to 3.92 Cr. Notably, cash flow from operating activities improved to 3.00 Cr in Mar'25, recovering from a negative 9.00 Cr in Mar'24, suggesting a positive shift in operational cash generation despite the overall challenges in revenue and profit.

Who are the top shareholders of the Zenlabs Ethica?

The top shareholders of Zenlabs Ethica are Preet Remedies Limited with 26.58%, followed by public shareholder Hitesh Popatlal Oswal at 6.79%. Individual investors collectively own 41.03%, with no mutual funds or foreign institutional investors holding shares.

The top shareholders of Zenlabs Ethica include Preet Remedies Limited, which holds the largest share at 26.58%. The highest public shareholder is Hitesh Popatlal Oswal, with a holding of 6.79%. Additionally, individual investors collectively hold 41.03% of the company's shares. There are no mutual funds or foreign institutional investors (FIIs) currently holding shares in the company.

Is Zenlabs Ethica overvalued or undervalued?

As of April 26, 2023, Zenlabs Ethica is considered very expensive and overvalued, with a PE ratio of 21.71, an EV to EBIT of 25.09, a low ROE of 2.59%, and a PEG ratio of 0.00, while its stock has underperformed the Sensex with a return of -21.76% compared to the Sensex's 7.61%.

As of 26 April 2023, the valuation grade for Zenlabs Ethica has moved from does not qualify to very expensive, indicating a significant shift in its valuation outlook. The company is currently assessed as overvalued. Key ratios include a PE ratio of 21.71, an EV to EBIT of 25.09, and a ROE of 2.59%, which highlight its high valuation relative to its earnings and equity returns.<BR><BR>In comparison to its peers, Zenlabs Ethica's PE ratio is notably higher than Life Insurance, which stands at 12.54, and Bajaj Finserv, with a PE of 35.83, indicating that while it is expensive, it is not the highest in its category. The PEG ratio of 0.00 suggests that there is no growth expected, further supporting the overvaluation claim. Additionally, Zenlabs Ethica's stock has underperformed against the Sensex over the past year, with a return of -21.76% compared to the Sensex's 7.61%, reinforcing the notion that the stock may be overpriced at its current valuation.

What is the technical trend for Zenlabs Ethica?

As of May 23, 2025, Zenlabs Ethica's trend is mildly bearish, with mixed indicators showing a mildly bullish weekly MACD but a bearish monthly MACD and daily moving averages.

As of 23 May 2025, the technical trend for Zenlabs Ethica has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands on a monthly basis are bearish, further supporting the overall bearish sentiment. The KST shows a mildly bullish trend weekly but is bearish monthly, indicating mixed signals. The Dow Theory reflects a mildly bullish trend on the weekly chart but shows no trend on the monthly chart. Overall, the current stance is mildly bearish with some mixed indicators, particularly in the weekly time frame.

What is the bonus history of the Zenlabs Ethica?

Zenlabs Ethica's bonus history includes a 1:20 bonus share announcement on October 11, 2018, with a record date of October 13, 2018, meaning shareholders received 1 additional share for every 20 shares held.

Zenlabs Ethica has a bonus history that includes a notable issue on October 11, 2018. The company announced a bonus in the ratio of 1:20, which means that for every 20 shares held, shareholders received 1 additional share. The record date for this bonus was October 13, 2018. If you have any more questions about Zenlabs Ethica or need further details, feel free to ask!

Has Zenlabs Ethica declared dividend?

Zenlabs Ethica Ltd has declared a 2% dividend, amounting to 0.2 per share, with an ex-date of July 29, 2022. However, the total returns over various periods have been negative, and the dividend yield remains at 0%.

Zenlabs Ethica Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: 0.2<BR>- Ex-date: Jul-29-2022<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -21.35%, the dividend return was 0%, resulting in a total return of -21.35%.<BR><BR>In the 1 year period, the price return was -23.56%, the dividend return was 0%, leading to a total return of -23.56%.<BR><BR>In the 2 years period, the price return was -29.74%, the dividend return was 0%, which resulted in a total return of -29.74%.<BR><BR>In the 3 years period, the price return was -1.39%, the dividend return was 0.50%, culminating in a total return of -0.89%.<BR><BR>In the 4 years period, the price return was 2.57%, the dividend return was 0.54%, resulting in a total return of 3.11%.<BR><BR>In the 5 years period, the price return was 31.82%, the dividend return was 0.98%, leading to a total return of 32.8%.<BR><BR>Overall, while Zenlabs Ethica Ltd has declared a dividend, the total returns over various periods show significant negative performance, particularly in the shorter terms, with only a modest recovery in the longer term. The dividend yield remains at 0%, indicating limited income generation from dividends relative to the share price.